OA
IRLA

Operose Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Operose Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89K Buy
+159
New +$3.65K ﹤0.01% 451
2026
Q1 		– Sell
-158
Closed -$106K – 640
2025
Q4 		$106K Hold
158
– – 0.02% 209
2025
Q3 		$51.5K Buy
+158
New +$52.6K 0.01% 255

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Operose Advisors's IRLA Position: Q2 2026 in Review

Operose Advisors opened a new position in IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026: 159 shares worth $2.89K. The stake represents ﹤0.01% of the portfolio and ranks #451 among its holdings. This is a return to the name: Operose Advisors previously reported a position in IRLA as recently as Q4 2025.

Operose Advisors first reported a position in IRLA in Q3 2025 and has held it in 3 quarters since. The position peaked at $106K in Q4 2025. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Operose Advisors held 159 shares of IRulya Therapeutics Inc. Common Stock worth $2.89K as of Q2 2026.
  • IRulya Therapeutics Inc. Common Stock was a new Operose Advisors position in Q2 2026.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of Operose Advisors's portfolio in Q2 2026, its #451 holding.
  • Operose Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2025 and has held it in 3 quarters since.
  • Operose Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $106K in Q4 2025.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.